260 related articles for article (PubMed ID: 32466781)
21. B7 score and T cell infiltration stratify immune status in prostate cancer.
Zhou Q; Li K; Lai Y; Yao K; Wang Q; Zhan X; Peng S; Cai W; Yao W; Zang X; Xu K; Huang J; Huang H
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34417325
[TBL] [Abstract][Full Text] [Related]
22. Different
Ye ZH; Long H; Zhao ZR
J Immunol Res; 2022; 2022():8513747. PubMed ID: 35528615
[TBL] [Abstract][Full Text] [Related]
23. Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy.
Liang Y; Yu M; Zhou C; Zhu X
Diagn Pathol; 2020 Jun; 15(1):67. PubMed ID: 32493336
[TBL] [Abstract][Full Text] [Related]
24. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
Pelekanou V; Carvajal-Hausdorf DE; Altan M; Wasserman B; Carvajal-Hausdorf C; Wimberly H; Brown J; Lannin D; Pusztai L; Rimm DL
Breast Cancer Res; 2017 Aug; 19(1):91. PubMed ID: 28784153
[TBL] [Abstract][Full Text] [Related]
25. Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma.
Shen YC; Hsu CL; Jeng YM; Ho MC; Ho CM; Yeh CP; Yeh CY; Hsu MC; Hu RH; Cheng AL
J Hepatol; 2020 Mar; 72(3):489-497. PubMed ID: 31634533
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
Chen S; Wang RX; Liu Y; Yang WT; Shao ZM
Int J Cancer; 2017 Mar; 140(6):1384-1395. PubMed ID: 27925176
[TBL] [Abstract][Full Text] [Related]
27. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant chemotherapy is associated with suppression of the B cell-centered immune landscape in pancreatic ductal adenocarcinoma.
Rupp L; Dietsche I; Kießler M; Sommer U; Muckenhuber A; Steiger K; van Eijck CWF; Richter L; Istvanffy R; Jäger C; Friess H; van Eijck CHJ; Demir IE; Reyes CM; Schmitz M
Front Immunol; 2024; 15():1378190. PubMed ID: 38629072
[TBL] [Abstract][Full Text] [Related]
29. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
30. Immunohistochemical analysis of PD-L1 and tumor-infiltrating immune cells expression in the tumor microenvironment of primary signet ring cell carcinoma of the prostate.
Teng QL; Yang XR; Wen S; Dai ZH; Wang HL; Liu TQ; Wang L; Fan B; Liu ZY
Asian J Androl; 2022; 24(5):525-532. PubMed ID: 35042311
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological and immunological profiles of prostate adenocarcinoma and neuroendocrine prostate cancer.
Huang G; Zhang H; Shi H; Zhang W; Wang T; Wang Z; Chen Q; Lian B; Li J; Yang G
World J Surg Oncol; 2022 Dec; 20(1):407. PubMed ID: 36572885
[TBL] [Abstract][Full Text] [Related]
32. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
[TBL] [Abstract][Full Text] [Related]
33. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
[TBL] [Abstract][Full Text] [Related]
34. Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8
Mo RJ; Han ZD; Liang YK; Ye JH; Wu SL; Lin SX; Zhang YQ; Song SD; Jiang FN; Zhong WD; Wu CL
Int J Cancer; 2019 Jun; 144(12):3099-3110. PubMed ID: 30537104
[TBL] [Abstract][Full Text] [Related]
35. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
36. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
37. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669
[TBL] [Abstract][Full Text] [Related]
38. Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy.
Kärjä V; Aaltomaa S; Lipponen P; Isotalo T; Talja M; Mokka R
Anticancer Res; 2005; 25(6C):4435-8. PubMed ID: 16334122
[TBL] [Abstract][Full Text] [Related]
39. Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer.
van der Linden RR; Haagmans BL; Mongiat-Artus P; van Doornum GJ; Kraaij R; Kadmon D; Aguilar-Cordova E; Osterhaus AD; van der Kwast TH; Bangma CH
Eur Urol; 2005 Jul; 48(1):153-61. PubMed ID: 15967266
[TBL] [Abstract][Full Text] [Related]
40. Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer.
Song IH; Heo SH; Bang WS; Park HS; Park IA; Kim YA; Park SY; Roh J; Gong G; Lee HJ
Cancer Res Treat; 2017 Apr; 49(2):399-407. PubMed ID: 27488875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]